Navigation Links
Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
Date:12/3/2007

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced it will report data from the Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets at the 49th annual meeting of the American Society of Hematology. The presentation is scheduled for Saturday, December 8, 2007, from 5:30 to 7:30 pm in Hall B3 and B4 at the Georgia World Congress Center in Atlanta. The presentation (Abstract # 1454, Board # 608) is titled: "Phase 1 Dose Escalation Study of TLK199 Tablets (TELINTRA), a Novel Glutathione Analog, in Myelodysplastic Syndrome." It will be presented during the poster session "Myelodysplastic Syndromes: Clinical Studies, Including Transplantation."

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in development for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, the ... cell and advanced therapies , has announced a ... company developing "tumor starvation" treatments for acute leukemia ... Under the agreement, Invetech will develop systems to ... Erytech,s proprietary ERYCAPS technology platform, which uses a ...
(Date:1/18/2017)... MIAMI , January 18, 2017 ... announced the company plans to publish an online ... the Company,s preliminary sales forecast for 2017. Management ... Company,s trialing ninety-day record sales performance from its ... recently announced entry into the Cannabis sector ...
(Date:1/18/2017)... Authority Chinese Food and Drug Administration CSL ... Institute Food and Drug Administration FORT ... Glaxo Smith Klein GlaxoWellcome Global Influenza ... Immune Targeting Systems Indian Association of ... Johnson & Johnson Krka Pharmaceuticals Medicago ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... Livingston, NJ (PRWEB) , ... January 17, 2017 , ... ... services and financial planning assistance to communities throughout the region, is launching a charity ... , Heart disease is by far the deadliest killer in America, and is responsible ...
Breaking Medicine News(10 mins):